[
  {
    "ts": null,
    "headline": "Dividend Growers: 2 Stocks That Could Be Worth $1 Trillion in 7 Years",
    "summary": "And that won't be the end of their growth stories.",
    "url": "https://finnhub.io/api/news?id=d3143f0fa070ad3126576591b019d22f631d2fcf8649ad0ebad8b646e75eb37e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769624700,
      "headline": "Dividend Growers: 2 Stocks That Could Be Worth $1 Trillion in 7 Years",
      "id": 138287512,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "And that won't be the end of their growth stories.",
      "url": "https://finnhub.io/api/news?id=d3143f0fa070ad3126576591b019d22f631d2fcf8649ad0ebad8b646e75eb37e"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Weighs Cancer Drug Pricing Pressure Against New Growth Paths",
    "summary": "FDA approved DARZALEX FASPRO for newly diagnosed multiple myeloma patients ineligible for stem cell transplant. Certain Johnson & Johnson cancer therapies were included in the first CMS drug price negotiation list under the Inflation Reduction Act. Johnson & Johnson submitted its Ottava robotic surgery platform to the FDA for authorization. Johnson & Johnson (NYSE: JNJ), trading at $224.44, is drawing fresh attention as these product and regulatory developments affect its pharma and MedTech...",
    "url": "https://finnhub.io/api/news?id=bf2bcc53de481d53267c5edf42e25b4b2b94cf253feed1f8bebc4cba150967d6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769623685,
      "headline": "Johnson & Johnson Weighs Cancer Drug Pricing Pressure Against New Growth Paths",
      "id": 138287514,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "FDA approved DARZALEX FASPRO for newly diagnosed multiple myeloma patients ineligible for stem cell transplant. Certain Johnson & Johnson cancer therapies were included in the first CMS drug price negotiation list under the Inflation Reduction Act. Johnson & Johnson submitted its Ottava robotic surgery platform to the FDA for authorization. Johnson & Johnson (NYSE: JNJ), trading at $224.44, is drawing fresh attention as these product and regulatory developments affect its pharma and MedTech...",
      "url": "https://finnhub.io/api/news?id=bf2bcc53de481d53267c5edf42e25b4b2b94cf253feed1f8bebc4cba150967d6"
    }
  },
  {
    "ts": null,
    "headline": "Should You Stay Invested in J&J Stock After Q4 Beat & Solid Guidance?",
    "summary": "JNJ beat Q4 expectations and guided 2026 sales to be in the range of $100-$101B, with Innovative Medicine and MedTech growth offsetting Stelara LOE.",
    "url": "https://finnhub.io/api/news?id=fe2d9b6b672cf8808e2ae2c99a2dc638700d6de8577bcac038499225e4cc8931",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769616600,
      "headline": "Should You Stay Invested in J&J Stock After Q4 Beat & Solid Guidance?",
      "id": 138285048,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "JNJ beat Q4 expectations and guided 2026 sales to be in the range of $100-$101B, with Innovative Medicine and MedTech growth offsetting Stelara LOE.",
      "url": "https://finnhub.io/api/news?id=fe2d9b6b672cf8808e2ae2c99a2dc638700d6de8577bcac038499225e4cc8931"
    }
  },
  {
    "ts": null,
    "headline": "Texas Instruments, Circle, Johnson & Johnson: Top Analyst Calls",
    "summary": "Yahoo Finance Senior Reporter Brooke DiPalma keeps track of several Wall Street analyst calls on top trending stocks, including calls around shares of Texas Instruments (TXN), Circle Internet Group (CRCL), and Johnson & Johnson (JNJ).To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.",
    "url": "https://finnhub.io/api/news?id=adccbeecb528d6b4f4cb0cf52969c97d8d247501b711e01298d323d16a97be06",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769613716,
      "headline": "Texas Instruments, Circle, Johnson & Johnson: Top Analyst Calls",
      "id": 138281459,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Yahoo Finance Senior Reporter Brooke DiPalma keeps track of several Wall Street analyst calls on top trending stocks, including calls around shares of Texas Instruments (TXN), Circle Internet Group (CRCL), and Johnson & Johnson (JNJ).To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.",
      "url": "https://finnhub.io/api/news?id=adccbeecb528d6b4f4cb0cf52969c97d8d247501b711e01298d323d16a97be06"
    }
  },
  {
    "ts": null,
    "headline": "Merck's Non-Oncology Drugs Q4 Performance: What to Expect",
    "summary": "MRK's focus shifts beyond Keytruda in Q4 as investors watch new products Capvaxive and Winrevair, as well as Animal Health business sales performance.",
    "url": "https://finnhub.io/api/news?id=6dd035107dd917d10cce0222e5b883f3a05e0749d794127b10a8ed0bf477692c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769613300,
      "headline": "Merck's Non-Oncology Drugs Q4 Performance: What to Expect",
      "id": 138285049,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "MRK's focus shifts beyond Keytruda in Q4 as investors watch new products Capvaxive and Winrevair, as well as Animal Health business sales performance.",
      "url": "https://finnhub.io/api/news?id=6dd035107dd917d10cce0222e5b883f3a05e0749d794127b10a8ed0bf477692c"
    }
  },
  {
    "ts": null,
    "headline": "Diaper Market Forecast and Company Analysis Report 2025-2033 Featuring Kao, Kimberly-Clark, P&G, SCA, Unicharm, Cott, Pigeon, Johnson & Johnson, Hengan International",
    "summary": "The global diaper market is set to grow from $94.68 billion in 2025 to $160.63 billion by 2033, showcasing a CAGR of 6.83%. Rising birth rates in emerging markets and increasing demand for incontinence care drive growth in both baby and adult diaper segments. Urbanization, higher disposable incomes, and awareness of hygiene standards fuel consumer preference for convenient and high-quality diapers. Sustainability trends are pushing demand for eco-friendly products. The U.S., Germany, China, and",
    "url": "https://finnhub.io/api/news?id=acc0e4700a2d6cee237d8d3e45c5d8c8dbace1dc822ac1f80d217d3f3a95618a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769611800,
      "headline": "Diaper Market Forecast and Company Analysis Report 2025-2033 Featuring Kao, Kimberly-Clark, P&G, SCA, Unicharm, Cott, Pigeon, Johnson & Johnson, Hengan International",
      "id": 138281460,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The global diaper market is set to grow from $94.68 billion in 2025 to $160.63 billion by 2033, showcasing a CAGR of 6.83%. Rising birth rates in emerging markets and increasing demand for incontinence care drive growth in both baby and adult diaper segments. Urbanization, higher disposable incomes, and awareness of hygiene standards fuel consumer preference for convenient and high-quality diapers. Sustainability trends are pushing demand for eco-friendly products. The U.S., Germany, China, and",
      "url": "https://finnhub.io/api/news?id=acc0e4700a2d6cee237d8d3e45c5d8c8dbace1dc822ac1f80d217d3f3a95618a"
    }
  },
  {
    "ts": null,
    "headline": "PayPal downgraded, UPS upgraded: Wall Street's top analyst calls",
    "summary": "PayPal downgraded, UPS upgraded: Wall Street's top analyst calls",
    "url": "https://finnhub.io/api/news?id=0a81fa8deae9d7bed70fcd939ef36b83960a790ebaefb317301eee199a801a75",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769611153,
      "headline": "PayPal downgraded, UPS upgraded: Wall Street's top analyst calls",
      "id": 138281387,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "PayPal downgraded, UPS upgraded: Wall Street's top analyst calls",
      "url": "https://finnhub.io/api/news?id=0a81fa8deae9d7bed70fcd939ef36b83960a790ebaefb317301eee199a801a75"
    }
  },
  {
    "ts": null,
    "headline": "Connecticut Innovations Banks $41.0 Million in Venture Proceeds in Q2 FY26",
    "summary": "Connecticut Innovations (CI), Connecticut's strategic venture capital arm, today announced that it invested approximately $16.2 million in 23 companies and venture funds during the second quarter of its fiscal year, ending December 31, 2025. CI's investments leveraged $253.2 million in outside capital and generated $41 million in proceeds during the quarter. To date in fiscal year 2026, CI has invested $27.5 million and leveraged $340.1 million.",
    "url": "https://finnhub.io/api/news?id=7468a7a3cd06d4e3da21e8ac9cfff1e65b8c8967294104cf45d57aa498197a61",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769608800,
      "headline": "Connecticut Innovations Banks $41.0 Million in Venture Proceeds in Q2 FY26",
      "id": 138281462,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Connecticut Innovations (CI), Connecticut's strategic venture capital arm, today announced that it invested approximately $16.2 million in 23 companies and venture funds during the second quarter of its fiscal year, ending December 31, 2025. CI's investments leveraged $253.2 million in outside capital and generated $41 million in proceeds during the quarter. To date in fiscal year 2026, CI has invested $27.5 million and leveraged $340.1 million.",
      "url": "https://finnhub.io/api/news?id=7468a7a3cd06d4e3da21e8ac9cfff1e65b8c8967294104cf45d57aa498197a61"
    }
  },
  {
    "ts": null,
    "headline": "CMS selects next batch of 15 high-cost medicines for third negotiation cycle",
    "summary": "The 15 drugs accounted for $27bn in spending via Medicare Part B and Part D between November 2024 and October 2025.",
    "url": "https://finnhub.io/api/news?id=1934eea251c629d11b9eedf631f389a3683800a20c7fd83d6320c306aa3c8579",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769604538,
      "headline": "CMS selects next batch of 15 high-cost medicines for third negotiation cycle",
      "id": 138280575,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The 15 drugs accounted for $27bn in spending via Medicare Part B and Part D between November 2024 and October 2025.",
      "url": "https://finnhub.io/api/news?id=1934eea251c629d11b9eedf631f389a3683800a20c7fd83d6320c306aa3c8579"
    }
  },
  {
    "ts": null,
    "headline": "Morgan Stanley Upgrades Johnson & Johnson (JNJ)",
    "summary": "Morgan Stanley Upgrades Johnson & Johnson (JNJ)",
    "url": "https://finnhub.io/api/news?id=d72945daa2a6e2d46bf0e279bf9ac8d4931f21675bc8beae14120ea0fb9933d1",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769601858,
      "headline": "Morgan Stanley Upgrades Johnson & Johnson (JNJ)",
      "id": 138280105,
      "image": "",
      "related": "JNJ",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=d72945daa2a6e2d46bf0e279bf9ac8d4931f21675bc8beae14120ea0fb9933d1"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson: Strong Momentum Heading Into 2026",
    "summary": "Johnson & Johnson remains a buy as business momentum accelerates, with Q4 revenue up 9.1% YoY and strong U.S. sales resilience.",
    "url": "https://finnhub.io/api/news?id=ebc238ea5a23fe7bde109bf513488c9019c94edf27c003a945e321b321a22fa5",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769593091,
      "headline": "Johnson & Johnson: Strong Momentum Heading Into 2026",
      "id": 138281143,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1396614976/image_1396614976.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Johnson & Johnson remains a buy as business momentum accelerates, with Q4 revenue up 9.1% YoY and strong U.S. sales resilience.",
      "url": "https://finnhub.io/api/news?id=ebc238ea5a23fe7bde109bf513488c9019c94edf27c003a945e321b321a22fa5"
    }
  },
  {
    "ts": null,
    "headline": "Simplicity Beats Complexity: The 3-Fund Strategy For Building Wealth",
    "summary": "Simplicity Beats Complexity: The 3-Fund Strategy For Building Wealth",
    "url": "https://finnhub.io/api/news?id=a7a222839f47baf466349fdbe86672ba176167edd671ab82aaa1abb5ce9e110c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769586300,
      "headline": "Simplicity Beats Complexity: The 3-Fund Strategy For Building Wealth",
      "id": 138280158,
      "image": "",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=a7a222839f47baf466349fdbe86672ba176167edd671ab82aaa1abb5ce9e110c"
    }
  }
]